Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B

☆ ClinicalTrials.gov Identifier: NCT00057265. Grant support: This study was sponsored by Idenix Pharmaceuticals, Inc. and Novartis Pharma AG. Financial disclosures: S. Zeuzem has received consulting fees from BMS, Gilead, GSK, Novartis, Roche and Schering-Plough and lecture fees from Idenix and Novartis. E. Gane has received consulting fees from Gilead, GSK and Novartis and honoraria from GSK, Idenix, Novartis and Roche. Y.-F. Liaw, Consultant for BMS, GSK, Novartis, Roche, Schering-Plough and SciClone; grant/research support from BMS, Idenix, Novartis, Roche, SciClone, and Gilead. S.-G. Lim has acted as a scientific advisor to Idenix, Novartis, and BMS and is on the speakers bureau for GSK and Schering-Plough. A. DiBisceglie: TBD. M Buti: Advisory board for Gilead, Novartis. Speaker: Gilead, Novartis, BMS, Schering-Plough. Editorial Board: Journal of Hepatology. A. Chuttaputti has no disclosures. J. Rasenack has no disclosures. J. Hou has provided scientific advice to Novartis, GSK and BMS. C. O’Brien: research grant support from Novartis, Idenix Pharmaceuticals. T.T. Nguyen: TBD. J. Jia is an investigator for the GLOBE trial and is the PI for the 015 study for Idenix and Novartis. T. Poynard: Investigator, speaker and advisory board for Idenix, Novartis, GSK, Schering, Vertex, Tibotec, BMS. B. Belanger is an employee of Idenix Pharmaceuticals. W. Bao is an employee of Novartis Pharmaceuticals. N.V. Naoumov is an employee of Novartis Pharma AG.

PII: S0168-8278(09)00063-4

doi: 10.1016/j.jhep.2008.12.019

© 2009 European Association for the Study of the Liver. Published by Elsevier Inc. All rights reserved.